Bosentan for high-risk outpatients with COVID-19 infection: a randomized, double blind, placebo-controlled trial

BACKGROUND: The endothelium is supposedly activated and damaged in COVID-19 because of endothelin-1 over-secretion. This study evaluates the effect of bosentan as an endothelin receptor blocker on the progression of disease in high-risk outpatients with COVID-19 infection. METHODS: From 15 December...

Descripción completa

Detalles Bibliográficos
Autores principales: Shahbazi, Shaahin, Vahdat Shariatpanahi, Zahra, Shahbazi, Erfan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404861/
https://www.ncbi.nlm.nih.gov/pubmed/37554128
http://dx.doi.org/10.1016/j.eclinm.2023.102117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404861/
https://www.ncbi.nlm.nih.gov/pubmed/37554128
http://dx.doi.org/10.1016/j.eclinm.2023.102117

Ejemplares similares